We hope many of you were able to watch the livestream from the Nightscout Foundation of our Fall 2017 DiabetesMine D-Data ExChange forum that took place on Thursday, Nov. 16, at Stanford University.

It’s hard to believe this is the 5th year we’ve been bringing people together for this biannual #DData gathering of leaders and passionate developers of diabetes technology! It’s the event that gave birth to the #WeAreNotWaiting hashtag and movement.

In those years we’ve seen exciting results that include partnerships, hirings, product development progress, big strides towards interoperability and FREEING THE DATA, and overall helping to forge new innovation pathways.

 

It’s also been a full 10 years since that “Open Letter to Steve Jobs” that started this whole journey for DiabetesMine.

And guess what?...

Shortly before this event, Bloomberg reported that “diabetes devices may be having their iPhone moment”...

They also quote a Jeffries analyst in New York saying, “This is a crossroads for diabetes technology”... as consumer tech giants like Apple, Google and Fitbit are starting to make a lot of noise about their involvement in diabetes.

NICE!!

We were very excited about the array of great presenters and topics at our Fall #DData17 event, and today we bring you a quick run-down with links to the presentations where possible. You can start by checking out my opening remarks here.

You can also view the agenda/program here, and access the event photos on our Facebook page.

 

Fall #DData17 Program Rundown

 

A great opening talk on Digital Health: Lessons Learned & Opportunities for Diabetes” by Mintu Turakhia, Executive Director of Stanford’s new Center for Digital Health. Due to Stanford’s policies, we can’t publish his entire slideset, but we did want to share this one illustration of the barriers that need to be overcome:

And you can learn about the Stanford Center for Digital Health here.

 

Dexcom - Breaking Open Medical APIs

We’ve been following Dexcom's progress and support of an open development environment since the company previewed their new collaborative developer portal at our Fall #DData event last year. They recently opened that publicly.

And they also recently did something pretty revolutionary in becoming the 1st U.S.-based medical device company to launch a public API.

Nate Heintzman, Director of Data Partnerships at Dexcom, was on hand to update us. See his slides here.

 

Embracing New ‘Beyond A1C’ Measures in Diabetes Product Development

JDRF recently announced two ground-breaking efforts supporting huge steps forward in creating tools that benefit patients:

* The Beyond A1c consensus initiative that codified “time in range” and other quality of life measures as real endpoints

* JDRF’s Call for Open Protocols to embrace patient-led innovations

Aaron Kowalski, JDRF’s Chief Mission Officer & VP of Research, provided insight on both of these initiatives in his presentation, here.  

 

Diabetes Innovation Headway: Lessons from Outside the U.S.

By popular demand, we invited two experts on the diabetes innovation landscape from Europe – to help us "learn from our international brethren."

First up, we heard from Kyle Rose, a veteran medtech industry expert on cultural differences and European markets who’s also a T1D himself and currently works with mySugr.

Kyle provided a fantastic overview of how language differences and variations in the healthcare and reimbursement systems impact D-innovation. See Kyle's slides here.

 

DIY Update from Europe - New #AndroidAPS Algorithms and More

We were delighted to include Adrian Tappe, joining us from Austria to represent the European DIY diabetes world. He is a talented programmer currently finishing his Master’s in Pervasive Computing, i.e. the Internet of Things.

Adrian made first contact with the Nightscout community in 2014 and soon joined the xDrip development team. In 2016, he joined the AndroidAPS development team, and has become a key figure in the German-speaking world.

His overview of his own story, and the progress of the AndriodAPS tool (300 daily active users in 11 languages, and growing daily) really stole the show! Not bad for his very first presentation in English. See Adrian’s slides here.

 

#WeAreNotWaiting Community Research

Ever wonder who exactly is active in the online #WeAreNotWaiting community? There’s now data on that!

Michelle Litchman, a Utah diabetes nurse and researcher, recently led a research team that won the Med X-Symplur Signals Challenge. Symplur Signals is a Twitter analysis software focused on health-related hashtags.

The challenge encouraged teams to submit a proposal on a research question that could be answered by examining Twitter data. Teams selected as semi-finalists recieved free access to Symplur for 30-days and had to complete their project during that timeframe.

Each semi-finalist team then submitted a report and a winner was selected.

We are excited that Michelle’s team was chosen to focus on #WeAreNotWaiting and #OpenAPS.

Michelle was unable to join #DData17 in person, but we’re grateful to OpenAPS creator Dana Lewis (who was part of this research team) for presenting the results.

See those research results slides here.

 

A Review of the First-Ever Hybrid Closed Loop: Minimed 670G from the Clinical and Patient POV

CDE and diabetes tech expert Gary Scheiner is pretty much a household name in this crowd. But ICYMI: he is owner and clinical director of Integrated Diabetes Services, a practice located just outside of Philadelphia specializing in intensive insulin therapy and advanced education. for children and adults. Gary Scheiner Medtronic 670G review

He’s author of 6 books on diabetes care including the best-selling “Think Like A Pancreas” and was named 2014 Diabetes Educator of the Year by AADE.  

He’s been a CDE for 22 years and T1D himself for 33 years.

Lucky for us, he volunteered to give this Fall’s #DData group his thoughts on using the new Medtronic 670G system – the first-ever hybrid closed loop system.

There are some VERY eye-opening observations to be had in Gary's analysis slides, viewable here.

 

Emerging Smart Pen Technology Forum

We were also psyched about this forum on the exciting emerging area of “smart” data-connected insulin pens. Connected pens have huge potential on many fronts:

  • Overall, there’s a lack of data on insulin use, and connected pens can help with that
  • They provide “decision support” for pen users, i.e. the dosing calculation power of a pump
  • They have the potential to be integrated into closed loop systems – allowing non-pumpers to take advantage of that advanced technology too

In fact, we had hoped do this session on Smart Pen Tech back in June at our Summer #DData event, but no one seemed ready to talk just then.

This time around, we were able to hear the latest updates, including never-before-unveiled product details, from:

We were told by some attendees that this session was “transformative” – so definitely worth checking out their slides at the links above!

 

FDA Update: Digital Health Software Precertification and Beyond

Stayce Beck leads an FDA team that reviews new diabetes devices prior to sale in the U.S.

She was previously team lead for the Artificial Pancreas project, and she and her colleague Courtney Lias were recently honored with a National Excellence in Management Award for the work they’ve done and their leadership in advancing AP innovations!

We were truly grateful to be able to host her yet again to update this #DData crowd on FDA’s new digital health software precertification program.

See Stayce’s slides here.  

 

New Frontiers: Blockchain Technology in Healthcare

Dr. Brigitte Piniewski joined us from Oregon-based ConsenSys -- a blockchain venture specifically working on a project called Healthcoin that has ambitious aspirations to apply “token-based approaches to enable self-correcting influences on the healthcare ecosystem.”

We were told if successful, this new model could help make significant strides in improving patient-centric value-based care.

To be honest, this presentation did little to pull the back the curtain on the mystery of blockchain tech in healthcare, but we know that many in the digital health community are still quite excited about it.

See Brigitte's slides here. And you can learn more about the topic in the MIT Technology Review journal here.

 

#DData Demos!

 This seasons array of new D-tools was as engaging as ever:

  • WellDoc’s BlueStar app – an FDA-cleared evidence-based solution that provides individualized real-time in-app coaching and support to patients with type 2 diabetes. WellDoc is collaborating with Samsung on this.
  • DreaMed Diabetes – which develops and commercializes a cloud-based decision support tool offering systematic analysis of a patient's data resulting in patient-specific optimal insulin treatment plans. They’re currently working with Glooko on a multi-national clinical trial for DreaMed Advisor.
  • Integrated Medical Sensors (IMS) – developing the first fully integrated wireless CGM platform with an incredibly tiny sensor. Their offering is patented at Caltech, and funded for commercialization by NSF and NIH. And they snagged the first place award in T1D Exchange’s 2016 ‘Diabetes Innovation Challenge.’
  • Calorie Mama app – Azumio™ is a leader in mobile health & fitness with more than 70M downloads to date on both iOS™ and Android® platforms. Their leading suite of apps includes Fitness Buddy, Glucose Buddy and their newest nutrition tracking app, Calorie Mama – which is photo-based and very much resembles the “See Food” app in the HBO series Silicon Valley ;)
  • One Drop Amazon Alexa / Echo – One Drop is of course a new players making a big splash with their designer BG meter, dynamic app and coaching services. Their newest offering combines their tech with voice recognition – sometimes writen off as a toy but with huge potential to not only to simplify people’s lives but help the many patients who need better accessibility due to vision impairments, etc.

Huge thanks to our Top Chef-style T1D experts reactor panel, who asked the demoer’s pointed questions:

- Patient Power User – PV Contest winner and advocate Mandy Jones

- National Advocate/Policy Leader - Aaron Kowalski of JDRF

- Industry Expert - Jonathan Fern of Abbott Diabetes Care

 

WORKSHOP: Patient-Led Research in Collaboration with Academia

Last but certainly not least, OpenAPS innovator Dana Lewis led an interactive workshop on taking a patient-centered approach to collaborative research.

Dana is now Principal Investigator (PI) for a Robert Wood Johnson Foundation funded grant to work to scale patient-led innovation and scientific discovery in more patient communities. She’s working directly with Stanford Medicine experts on this, and we were privileged to have key collaborator Dr. Larry Chu on hand to talk about his amazing accomplishments including patient leaders in the Stanford Medicine X program.

See those combined workshop slides here.

 

Making a Difference

Post-event, we were delighted to hear feedback along these lines:

I was again impressed with the event and continue to find it the most interesting and informative in this space. Having been an attendee for the last four years, I am especially encouraged to see the collaboration and spirit of cooperation growing between the DIY community and industry. Well done on getting there!" – John Sjolund, Bigfoot Biomedical

This is a very important event for the diabetes community.” – our Stanford Medicine hosts

It was a magnificent event. You are truly making a difference.” – Kyle Rose, International Medtech Consultant, MySugr 

 

As always, a HUGE THANK YOU to all who supported and attended this event! Our Tidepool co-hosts, 2017 program sponsors, speakers, demoers, panelists, Nightscout and OpenAPS communities, and of course, ALL the innovators making a difference in advancing in advancing  diabetes tech!

Disclaimer: Content created by the Diabetes Mine team. For more details click here.

Disclaimer

This content is created for Diabetes Mine, a consumer health blog focused on the diabetes community. The content is not medically reviewed and doesn't adhere to Healthline's editorial guidelines. For more information about Healthline's partnership with Diabetes Mine, please click here.